Scholarlink

<p>Alzheimer’s disease (AD) drug development has undergone cycles, driven initially by amyloid-β–based hypotheses and later setbacks by clinical failures. Recent advances in biotechnology, improved understanding of AD pathogenesis, and unmet medical needs have revitalized the field. This new wave is exemplified by lecanemab, the first fully FDA-approved disease-modifying therapy in two decades. We review approved and clinical-stage AD therapeutics using data from Cortellis and the FDA.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Innovation breakthrough in the Alzheimer’s disease pharmaceutical industry

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年3月2日

查看全文
  • Hua Cheng,
  • Leyi Kang,
  • Yulong Xu,
  • Rudolph E. Tanzi,
  • Can Zhang,
  • Changning Wang

摘要

Alzheimer’s disease (AD) drug development has undergone cycles, driven initially by amyloid-β–based hypotheses and later setbacks by clinical failures. Recent advances in biotechnology, improved understanding of AD pathogenesis, and unmet medical needs have revitalized the field. This new wave is exemplified by lecanemab, the first fully FDA-approved disease-modifying therapy in two decades. We review approved and clinical-stage AD therapeutics using data from Cortellis and the FDA.